If targeting homologous recombination does not offer specific therapeutic perspectives for ALT+ cancer treatment, the discovery that disrupting the interaction between TSPYL5 and USP7 seems to specifically induce ALT+ cell death offers alternative perspectives [7, 8]. The gene discussed is GPT; the disease is cancer.